Ironwood Pharmaceuticals (IRWD) reported adjusted earnings of 2 cents per share for the fourth quarter of 2024, missing the Zacks Consensus Estimate of 10 cents. The company had recorded break-even earnings in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Total revenues in the fourth quarter were $90.5 million, which also missed the Zacks Consensus Estimate of $92 million. The top line decreased almost 23% year over year due to the decrease in collaborative arrange ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Greg Martini - Chief Financial Officer Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Jason Butler - Citizens JMP Matt Cowper - Leerink Partners David Amsellem - Piper Sandler Operator My name is Kathleen, and I will be your conference operator today. At this time, I would like to welcome ...

Ironwood Pharmaceuticals (IRWD) Q4 2024 Earnings Call March 31, 2025 12:02 PM ET Company Participants Greg Martini - CFOThomas McCourt - CEOMichael Shetzline - SVP, Chief Medical Officer and Head of Research & DevelopmentJason Butler - Managing Director & Biotechnology Equity ResearchKatherine Wang - Equity AssociateMatthew Cowper - Vice President - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareDavid Amsellem - Sr. Research Analyst Operator My ...

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -80%. A quarter ago, it was expected that this drugmaker would post earnings of $0.09 per share when it actually produced earnings of $0.02, delivering a surprise of -77.78%.Over the last four quarters, ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance – 2024 Ironwood revenue of $351 million, GAAP net income of $2 million and adjusted EBITDA of $101 million – BOSTON, Mass., February 27, 2025 — Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its fourth quarter ...

Core Viewpoint - Ironwood Pharmaceuticals has initiated a rolling new drug application for apraglutide to treat short bowel syndrome, while also undergoing significant corporate restructuring, including a workforce reduction of nearly 50% [1][2][7]. Group 1: Drug Development and NDA Submission - The rolling NDA submission for apraglutide is aimed at treating short bowel syndrome patients dependent on parenteral support, with completion expected in Q3 2025 [1]. - Ironwood acquired the rights to apraglutide through the acquisition of VectivBio in June 2023, and the drug has shown promising results in phase III studies [3]. - Data from the STARS Extend study indicated that longer exposure to apraglutide led to an increased number of patients achieving enteral autonomy, which is a key goal for SBS patients [4]. Group 2: Corporate Restructuring - The company plans to reduce its workforce by almost 50%, primarily affecting the field force, and will close the phase II exploratory study STARGAZE [2][7]. - Anticipated restructuring charges are estimated to be around $20-$25 million, primarily incurred in the first half of 2025 [7]. - The strategic reorganization is expected to yield annual operating expense savings of approximately $55-$60 million [8]. Group 3: Financial Guidance and Market Performance - Ironwood expects total revenues in the range of $260-$290 million for 2025, which is below the Zacks Consensus Estimate of $329.7 million [9]. - U.S. sales of Linzess are projected to be between $800-$850 million, and the company anticipates delivering adjusted EBITDA of over $85 million in 2024 [9]. - Following the announcements, Ironwood's shares fell by 11.6% and have decreased by 73.8% over the past year, contrasting with a 5.8% decline in the industry [2].

The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off the second phase of a landmark process that aims to make costly medications more affordable for seniors. Topping the list are Novo Nordisk's blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product in the talks since they all share the same active ingredient: semaglutide. Those ...

Ironwood Pharmaceuticals, Inc. (IRWD) reported adjusted earnings of 2 cents per share for the third quarter of 2024, missing the Zacks Consensus Estimate of 9 cents. The company had recorded adjusted earnings of 12 cents per share in the year-ago quarter.Total revenues in the third quarter were $91.6 million, which beat the Zacks Consensus Estimate of $89 million. However, the top line decreased almost 19.4% year over year due to the decrease in collaborative arrangements revenues related to its sole market ...

Financial Data and Key Metrics Changes - In Q3 2024, Ironwood reported US net sales of LINZESS at $226 million, reflecting a 19% year-over-year decline [11][18] - Ironwood's total revenue for Q3 was $92 million, also down 19% year-over-year [18] - GAAP net income for the quarter was $4 million, with adjusted EBITDA reported at $26 million [18][19] - The company generated $10 million in operating cash flow during the third quarter [10] Business Line Data and Key Metrics Changes - LINZESS experienced a 13% increase in prescription demand year-over-year, marking the seventh consecutive quarter of double-digit growth in new to brand prescriptions [6][11] - Despite strong volume growth, LINZESS faced pricing pressures primarily due to an increase in Medicaid prescriptions [6][11] Market Data and Key Metrics Changes - The company noted that LINZESS US net sales were down 19% year-over-year, with a year-to-date decline of 13% compared to the same period in 2023 [18] - The company is closely monitoring Medicaid utilization trends and legislative changes that may impact LINZESS [11][18] Company Strategy and Development Direction - Ironwood is focused on maximizing LINZESS profits and cash flow while advancing the apraglutide NDA submission, expected in Q1 2025 [10][19] - The company has decided not to pursue an exclusive license for CNP104 and has halted recruitment for the IW-3300 Phase 2 study to focus on high-value projects [9][10] - The strategic priority includes delivering sustained profits and cash flow, with an emphasis on managing pricing pressures for LINZESS [10][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing pricing headwinds for LINZESS but expressed confidence in the brand's market leadership and demand growth [10][20] - The company plans to provide further guidance on LINZESS demand and pricing expectations for 2025 early next year [11][19] Other Important Information - Ironwood amended its credit facility, providing $50 million in additional liquidity and extending maturity to December 2028 [18] - The company ended Q3 with $88 million in cash and cash equivalents, indicating a strong capital position to support future initiatives [18] Q&A Session Summary Question: Commercial margin for LINZESS and impact of Part D redesign in 2025 - Management acknowledged pricing headwinds in 2025 and indicated that guidance for that year will be provided early next year, while expressing satisfaction with current commercial margins [24][25] Question: Potential for renegotiation with payers as LINZESS approaches the end of its commercial life - Management is critically evaluating how to increase profits and cash flow, including exploring new contracting strategies and optimizing spending [28][30] Question: Drivers of demand growth and promotional strategies - Management emphasized the importance of growing the market and capturing share, while also focusing on efficient demand generation and lifecycle management opportunities [32][33] Question: Commercial readiness for apraglutide - Management highlighted ongoing preparations for market readiness, including disease awareness programs and building core capabilities for patient support [35][36] Question: Expected increase in SG&A costs for apraglutide prelaunch - Management indicated that guidance for 2025 will be provided next year, noting existing commercial infrastructure will support the launch [43][44] Question: Sales force strategy for apraglutide - Management expressed confidence in integrating apraglutide into the existing sales force, leveraging their experience in gastroenterology [46][47]

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -77.78%. A quarter ago, it was expected that this drugmaker would post earnings of $0.17 per share when it actually produced break-even earnings, delivering a surprise of -100%.Over the last four quarters, ...